Please assess the completion status of the following clinical trial:

Trial Title: Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in Protocol FB401-01, completed through Week 20 visit and able to directly enroll into this (FB401-02) study~* Refrain from use of all other atopic dermatitis treatments, unless given permission by medical monitor~Exclusion Criteria:~* Subject experienced a serious adverse event or severe adverse event attributable to study drug in Protocol FB401-01~* Severe concomitant illness that, in the Investigator's opinion, would adversely affect subject participation in the study, whether medical or psychological~* Pregnant (or planning to become pregnant during the period of the study) or lactating females

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FB-401 (Type: EXPERIMENTAL): FB-401 applied topically

Based on this trial design, predict the completion outcome and termination type (if applicable).